Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q2 2026 · 10-Q
Revenue$411.00K$411.00K−70.4% vs Q2 2025 Net Income-$9.01M-$9.01MN/M vs Q2 2025 EPS Diluted-$1.31-$1.31N/M vs Q2 2025 Operating Income-$9,057,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,631,000N/M Margins · derivedOperating margin-2203.6%−2093.0 pt vs Q2 2025
Net margin-2191.2%
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end